SCHEMBL144182

SCHEMBL144182

O=Cc1ccc2[nH]c3c(C(=O)O)cc(Br)nc3c2c1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIF11 P52732 2/20 0.40
DHODH Q02127 2/20 0.36
PIM1 P11309 1/20 0.34
PIM3 Q86V86 1/20 0.34
MPL P40238 1/20 0.33
CYP2A6 P11509 1/20 0.33
GSK3B P49841 1/20 0.33
EPRS1 P07814 1/20 0.33
ALDH1A1 P00352 3/20 0.33
KDM4E B2RXH2 3/20 0.33
LMNA P02545 1/20 0.33
HSD17B10 Q99714 1/20 0.33
PBRM1 Q86U86 1/20 0.32
UNG P13051 1/20 0.31
GRIK1 P39086 1/20 0.31
GRIA1 P42261 1/20 0.31
GRIA2 P42262 1/20 0.31
GRIA3 P42263 1/20 0.31
GRIA4 P48058 1/20 0.31
GRIK2 Q13002 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL143722 0.86 NR4A2 (0.38) KIF11PIM1PIM3MPLALDH1A1
SCHEMBL137418 0.76 JAK2 (0.41) KIF11PIM1PIM3MPLGSK3B
SCHEMBL19595053 0.67 MEN1 (0.46) KIF11PIM1PIM3ALDH1A1HSD17B10
Benzene SCHEMBL28184721 0.66 KIF11 (0.81) KIF11PIM1PIM3CYP2A6ALDH1A1
SCHEMBL6299735 0.66 KIF11 (0.81) KIF11PIM1PIM3CYP2A6ALDH1A1
SCHEMBL6518705 0.65 SMAD3 (0.62) CYP2A6ALDH1A1KDM4ELMNAHSD17B10
SCHEMBL30961885 0.64 KDM4E (0.63) KIF11ALDH1A1KDM4ELMNAHSD17B10
SCHEMBL7003134 0.64 KIF11 (0.56) KIF11PIM1PIM3CYP2A6GSK3B
SCHEMBL28662175 0.63 PTPN1 (0.51) ALDH1A1KDM4EHSD17B10UNG
SCHEMBL10228588 0.63 PTPN1 (0.51) PIM1ALDH1A1KDM4EUNG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8815840-B2 Carbazole and carboline kinase inhibitors BRISTOL-MYERS SQUIBB COMPANY (US) 2014-08-26 US disclosed
EP-2370407-B1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL MYERS SQUIBB CO (US) 2014-06-18 EP disclosed
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2012-03-08 US disclosed
EP-2370407-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS Bristol-Myers Squibb Company (US) 2011-10-05 EP disclosed
WO-2010080474-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120058988-A1 CARBAZOLE AND CARBOLINE KINASE INHIBITORS JAK2, JAK1, JAK3 KIF11 2231/4885DHODH 3348/4885PIM1 101/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.